SIMCERE PHARMA (02096) Enters into Exclusive Promotion Service Agreement with Lynk Pharmaceuticals for Zeputinib Dermatological Indications

SIMCERE PHARMA (02096) announces that on November 2, 2026, the Group and Lynk Pharmaceuticals (Zhejiang) Co., Ltd. (Lynk Pharmaceuticals) further entered into a collaboration with respect to zeputinib, a selective JAK1 inhibitor. The Group will obtain exclusive commercialization rights in mainland China, Hong Kong, Macau, and Taiwan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and other dermatological indications. The Group and Lynk Pharmaceuticals entered into a collaboration in March 2022, obtaining exclusive commercialization rights in mainland China, Hong Kong, Macau, and Taiwan for zeputinib for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). This collaboration will further expand the commercialization potential of zeputinib and improve the Group's product portfolio in the field of autoimmune diseases. Zeputinib is a highly selective, oral second-generation JAK1 inhibitor independently developed by Lynk Pharmaceuticals and is currently being developed for the treatment of inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis. Zeputinib has completed a pivotal Phase III clinical study for atopic dermatitis, and the New Drug Application (NDA) for the treatment of moderate-to-severe AD was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in April 2026. The Phase III clinical study of zeputinib for the treatment of rheumatoid arthritis has been completed, and the Phase III clinical development program for ankylosing spondylitis is also ongoing.